Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.

Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH.

Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. Epub 2016 Mar 17.

2.

COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.

Freitas AC, Shiguihara RS, Monteiro RT, Pazeto TL, Coelho JC.

Arq Bras Cir Dig. 2016 Mar;29(1):21-5. doi: 10.1590/0102-6720201600010006. English, Portuguese.

3.

Outcomes Between Elderly and Young Hepatocellular Carcinoma Living Donor Liver Transplantation Recipients: A Single-Center Experience.

Li HY, Wei YG, Yan LN, Li B.

Medicine (Baltimore). 2016 Feb;95(5):e2499. doi: 10.1097/MD.0000000000002499.

4.

Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A.

World J Gastroenterol. 2016 Jan 7;22(1):232-52. doi: 10.3748/wjg.v22.i1.232. Review.

5.

Hepatocellular carcinoma: From diagnosis to treatment.

Waghray A, Murali AR, Menon KN.

World J Hepatol. 2015 May 18;7(8):1020-9. doi: 10.4254/wjh.v7.i8.1020. Review.

6.

2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Korean Liver Cancer Study Group (KLCSG).; National Cancer Center, Korea (NCC)..

Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.

7.

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Korean Liver Cancer Study Group (KLCSG).; National Cancer Center, Korea (NCC)..

Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.

8.

Histotripsy methods in mechanical disintegration of tissue: towards clinical applications.

Khokhlova VA, Fowlkes JB, Roberts WW, Schade GR, Xu Z, Khokhlova TD, Hall TL, Maxwell AD, Wang YN, Cain CA.

Int J Hyperthermia. 2015 Mar;31(2):145-62. doi: 10.3109/02656736.2015.1007538. Epub 2015 Feb 24. Review.

9.

From minimal to maximal surgery in the treatment of hepatocarcinoma: A review.

Perini MV, Starkey G, Fink MA, Bhandari R, Muralidharan V, Jones R, Christophi C.

World J Hepatol. 2015 Jan 27;7(1):93-100. doi: 10.4254/wjh.v7.i1.93. Review.

10.

Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.

Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A.

Am J Med. 2015 Jan;128(1):90.e1-7. doi: 10.1016/j.amjmed.2014.07.027. Epub 2014 Aug 10.

11.

Predicting recurrence patterns after resection of hepatocellular cancer.

Lee SY, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR.

HPB (Oxford). 2014 Oct;16(10):943-53. doi: 10.1111/hpb.12311. Epub 2014 Jul 16.

12.

Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice.

Zhang ZJ, Yang YK, Wu WZ.

J Transl Med. 2014 Feb 28;12:57. doi: 10.1186/1479-5876-12-57.

13.

Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times.

Squires MH 3rd, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF, Knechtle SJ, Staley CA 3rd, Maithel SK.

J Surg Oncol. 2014 May;109(6):533-41. doi: 10.1002/jso.23531. Epub 2013 Dec 17.

14.

Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies.

Lee Cheah Y, K H Chow P.

Liver Cancer. 2012 Nov;1(3-4):183-9. doi: 10.1159/000343832. Review.

15.

Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Lei JY, Yan LN, Wang WT.

World J Gastroenterol. 2013 Jul 21;19(27):4400-8. doi: 10.3748/wjg.v19.i27.4400.

16.

Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Wei Z, Doria C, Liu Y.

Clin Med Insights Oncol. 2013 May 20;7:87-102. doi: 10.4137/CMO.S7633. Print 2013.

17.

Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model.

Vlaisavljevich E, Kim Y, Allen S, Owens G, Pelletier S, Cain C, Ives K, Xu Z.

Ultrasound Med Biol. 2013 Aug;39(8):1398-409. doi: 10.1016/j.ultrasmedbio.2013.02.005. Epub 2013 May 15.

18.

Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study.

Cillo U, Vitale A, Dupuis D, Corso S, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Zanus G.

PLoS One. 2013;8(2):e57249. doi: 10.1371/journal.pone.0057249. Epub 2013 Feb 21.

19.

Current status of multimodal & combination therapy for hepatocellular carcinoma.

Yang J, Yan L, Wang W.

Indian J Med Res. 2012 Sep;136(3):391-403. Review.

20.

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma.

Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP.

Liver Transpl. 2012 Dec;18(12):1471-8. doi: 10.1002/lt.23551.

Supplemental Content

Support Center